Umoja Biopharma has announced the closing of an oversubscribed $100m Series C financing round, which will enable the company to progress its in vivo chimeric antigen receptor (CAR)-T cell therapy ...

GeekWire Award finalists for Health Innovation of the Year are dominated by ventures that aim to outwit cancer with ...

AbbVie has signed a wide-ranging collaboration with Umoja Biopharma in the area of ‘in situ’ or in vivo cell therapy, an emerging strategy that does away with the need to harvest, modify ...

Dr. Luke Walker, chief medical officer of Umoja Biopharma. (LinkedIn Photo) — Seattle’s Umoja Biopharma named Dr. Luke Walker as its chief medical officer. He will oversee the company’s ...

Leads the development of in vivo cell therapies at Umoja Biopharma, working to unlock the full potential of CAR T cells for cancer and other serious diseases. The company’s state-of-the-art ...

Scott Myers currently chairs the boards of directors for Umoja BioPharma, Zentalis Pharmaceuticals (ZNTL), Convergent Therapeutics, and Dynavax Technologies (DVAX). He was also President and CEO of ...